IDH2
The efficacy of enasidenib in patients with AML depends on the mutation type.
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Advertisement
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.